BGI Genomics

An estimated 23 million miscarriages occur worldwide each year, with approximately 15% of recognized pregnancies ending in miscarriage[5]. Beyond the physical and emotional impact, understanding why a pregnancy ends can help families and clinicians determi

As Breast Cancer Awareness Month 2026 highlights the need for more equitable cancer care, Thailand's efforts to expand access to hereditary cancer testing offer a practical example of how healthcare systems can turn genomic advances into patient benefits.

Commemorating BGI Group’s 27th anniversary, BGI Genomics introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-scale genetic

BGI Genomics announced the launch of its LUM + fFN Dual-Biomarker Rapid Test for preterm birth risk assessment, a colloidal gold test designed to provide a 10-minute, instrument-free lateral-flow readout. The product reflects BGI Genomics’ broader effort t

BGI Genomics has become aware that, on October 28, 2026, the United States Department of Homeland Security added BGI Genomics to the Uyghur Forced Lab...

BGI Genomics announced that its VISTA Chromosome Sequencing product for amniotic fluid samples—the Chromosome aneuploidy and copy number variants Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method)—has received the CE-IVDR certifi

NOVA Newborn Metabolic Disease Screening

BGI Genomics, founded in China’s genomics industry, operates a global marketing and service network spanning over 100 countries and all provinces and regions in China, offering full-industry-chain and multi-application solutions.

BGI JAPAN provides high-quality, cost-effective DNA and RNA sequencing analysis services and NGS solutions for research applications.